Efforts to prevent smoking, obesity could delay the need for angioplasty and stenting

Smokers needed their blocked arteries fixed nearly a decade earlier than non-smokers, and patients with obesity underwent these procedures four years earlier than non-obese patients, according to a new statewide study.

The research included patients without a history of heart attack who were treated at hospitals across Michigan participating in BMC2, the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. The patients had undergone angioplasty and/or stenting to widen or unblock their coronary arteries and restore blood flow. Almost all of them had at least one traditional risk factor, including smoking, obesity, high blood pressure, high cholesterol and diabetes. Most had three or more.

Additionally, women generally had their first procedure at a later age than men. Over the past decade, among patients undergoing their first angioplasty or stent procedure, the rates of obesity and diabetes have increased, while smoking and high cholesterol have decreased.

Smoking is a completely preventable risk factor. If we direct additional efforts at preventing smoking and obesity we could significantly delay the onset of heart disease and the need for angioplasty and stenting."

Devraj Sukul, M.D., M.Sc., senior author, interventional cardiologist and clinical lecturer at the University of Michigan Health Frankel Cardiovascular Center

Smoking cessation is a growing focus of the Michigan Collaborative Quality Initiatives, of which BMC2 is a member.

"In Michigan, we will work to help every smoker quit at the time of cardiac care because it is an unmatched teachable moment for patients," said Michael Englesbe, M.D., a surgeon and professor at Michigan Medicine who serves as portfolio medical director for the Collaborative Quality Initiatives.

Source:
Journal reference:

Gurm, Z., et al. (2021) Prevalence of coronary risk factors in contemporary practice among patients undergoing their first percutaneous coronary intervention: Implications for primary prevention. PLOS ONE. doi.org/10.1371/journal.pone.0250801.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
What is the role of monoclonal antibody therapy in treating COVID-19?